UPDATE 8/5/2020 Referral and Evaluation / Admission Policy

Paul Marron
Paul Marron
August 4, 2020

 Effective 8/5/2020 and until further notice, due to the ongoing COVID-19 pandemic and ever-changing Best Practice guidelines, we can accept for consideration of on-site evaluation and admission referrals of patients from hospital units, given 1) such referrals will be coming to us on a bed-to-bed basis; 2) such referrals will have had a negative result Rapid COVID-19 test within 12 hours prior to their hospital discharge; and 3) such referrals will have exited the hospital enroute to Tully Hill wearing an appropriate mask.  We also require that that test result be received by Tully Hill no later than the time and day of the patient’s scheduled arrival for their on-site evaluation. 

Referrals of all other patients who through our Intake screening process are deemed by our medical staff to have had high-risk exposure to COVID-19 will be considered on a case-by-case basis.

Thank you for working with us and understanding the need to keep our patients and employees safe and healthy, during the COVID-19 pandemic.  

Paul Marron

Director of Business Development

Paul Marron, Director of Business Development, joined Tully Hill Chemical Dependency Treatment Center in July 2012. Mr. Marron graduated Magna Cum Laude from both Saint Bonaventure University with a BA, History/Pre-Law and Boston University with his MS, Public Relations. He worked most recently at Central New York Eye & Tissue Bank where he served as their Director of Business Development. He has extensive experience in healthcare administration, contracting, marketing and development in Central New York.